mRNA Cancer Vaccine Expression and Translation Assay Services

Evaluate client mRNA cancer vaccine constructs for antigen expression and translation performance in mammalian cell lines or cell-free translation systems, with reporter and immunodetection readouts, dose-response and time-course testing, and QC controls reported as relative expression and translation data.

What This Assay Service Covers

This service is built for research teams that need early, assay-level evidence of how an mRNA cancer vaccine construct performs before committing to downstream immunogenicity or animal work. Projects typically begin with a client-supplied or CRO-prepared mRNA construct, followed by an mRNA integrity and purity quality check, delivery into mammalian cell lines by transient transfection or evaluation in a cell-free translation system, and readouts for protein expression and translation efficiency across dose and time.

Engagements follow a defined path: study-plan scoping, mRNA quality check, antigen expression and translation testing in the agreed assay system, controls and viability assessment, and reporting. Deliverables include an expression data report, a translation efficiency summary, mRNA quality check records, assay control documentation, and dose-response and time-course tables. Constructs, cell lines, dose ranges, time points, and readout formats are defined per project during scoping.

Downstream dendritic cell maturation and antigen presentation assays can investigate antigen presentation after vaccine expression has been established.

Assay Capabilities You Can Scope

Mammalian Cell Expression Assays

Transient transfection of client mRNA constructs into mammalian cell lines, with reporter assay or immunodetection readouts to assess antigen expression. Cell line choice and transfection format are agreed during project design.

Cell-Free Translation Assays

Cell-free translation systems for constructs where a cell-free readout is preferred, reporting relative translation signals alongside appropriate assay controls.

Dose-Response and Time-Course Design

Testing across a scoped range of mRNA doses and sampling time points so that expression and translation signals can be compared within a single, consistent assay design.

Translation Efficiency Quantification

Quantification of relative translation efficiency from assay readouts, reported with the controls and replicate structure defined in the agreed study plan.

How an Assay Engagement Runs

Scope and Assay Design We agree the constructs to be tested, the assay system (mammalian cell line or cell-free translation), readout type, dose range, time points, and controls in a written study plan before work begins.

Construct Intake and mRNA Quality Check Client-supplied or CRO-prepared mRNA is received and checked for integrity and purity as the starting QC step for the assay.

Expression and Translation Testing Constructs are delivered into mammalian cells by transient transfection or evaluated in cell-free translation systems, with reporter and immunodetection readouts collected across the scoped doses and time points.

Controls and Viability Assessment Positive and negative assay controls are run alongside test samples, and a cell viability or toxicity control is included where relevant to support interpretation of the expression signals.

Deliverables

Deliverable	What it covers
Expression data report	Tabulated reporter and immunodetection readouts for each mRNA construct tested, with relative expression signals across the doses and time points defined in the project scope.
Translation efficiency summary	Quantified translation efficiency comparisons between constructs and against the positive and negative assay controls included in the run.
MRNA quality check record	Integrity and purity assessment results for the client-supplied or CRO-prepared mRNA before it enters transfection or cell-free translation testing.
Assay control documentation	Records of positive and negative controls, transfection controls, and cell viability or toxicity checks used to support interpretation of the expression data.
Dose-response and time-course tables	Structured data tables for the dose levels and sampling times agreed during project design, formatted for internal candidate comparison.

Why choose our mRNA expression and translation assay services

Assay formats matched to the question

Projects can be run in mammalian cell lines by transient transfection or in cell-free translation systems, depending on whether the client needs a cell-context expression readout or a direct translation performance check. The format is agreed during project design so the readout fits the candidate screening decision.

Readouts built for candidate comparison

Controls and QC built into every run

Each project includes mRNA integrity and purity checks before testing, plus positive and negative assay controls, transfection controls, and cell viability or toxicity checks. These controls support interpretation of the expression data and are documented in the final report.

Clear scope boundaries

This is an expression and translation assay service. It reports relative expression and translation signals for client mRNA cancer vaccine constructs and does not include immunogenicity testing, animal efficacy studies, or mRNA manufacturing. Related work can be discussed separately when a project requires it.

Research reference

1. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation

Nature Communications. 2024. DOI: 10.1038/s41467-024-50093-7.

View article

Ready to evaluate your mRNA cancer vaccine construct?

Share your construct design, preferred assay format, and readout requirements. Our team will outline a scoped expression and translation assay plan with defined controls, time points, and deliverables for your review.

Functional follow-up can include antigen-specific T cell response assays when antigen-responsive immune activity is the next endpoint.

Request a scoped assay plan